• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by BioVie Inc.

    3/25/26 5:00:26 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIVI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    BIOVIE INC.

    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    09074F504

    (CUSIP Number)
    Cuong Do
    680 W Nye Lane, Suite 201
    Carson City, NV, 89703
    (775) 888-3162

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    01/05/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    09074F504


    1 Name of reporting person

    DO CUONG V
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    399,018.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    399,018.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    399,018.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.03 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    09074F504


    1 Name of reporting person

    Do & Rickles Investments, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    398,111.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    398,111.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    398,111.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.02 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Class A Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    BIOVIE INC.
    (c)Address of Issuer's Principal Executive Offices:

    680 W Nye Lane, Suite 201, Carson City, NEVADA , 89703.
    Item 2.Identity and Background
    (a)
    This Schedule 13D is filed by the following persons (collectively, the "Reporting Persons"), pursuant to their agreement to the joint filing of this Schedule 13D attached hereto as Exhibit 99.2: (i) Cuong Do; and (ii) Do & Rickles Investments, LLC.
    (b)
    The address for each of the Reporting Persons is c/o BioVie Inc., 680 W Nye Lane Suite 201, Carson City, NV 89703.
    (c)
    Mr. Do's principal occupation is President and Chief Executive Officer of the Issuer. Do & Rickles Investments, LLC is a limited liability company incorporated in Delaware, which is 100% owned by Mr. Do, and his wife. The principal business of Do & Rickles Investments, LLC is holding the investments of Mr. Do and his wife.
    (d)
    During the last five years, neither Reporting Person has been convicted in a criminal proceeding.
    (e)
    During the last five years, neither Reporting Person has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Mr. Do is a citizen of the United States.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The Reporting Persons acquired the Class A Common Stock beneficially owned by Mr. Do for cash using personal funds or as compensation for serving as the President and Chief Executive Officer of the Issuer. On March 4, 2024, Do & Rickles Investments, LLC purchased 50 warrants at a combined purchase price of $150.00 for each share of Class A Common Stock and accompanying warrant, after giving effect to the Reverse Stock Splits that the Issuer effected on August 6, 2024 and July 7, 2025, in connection with the Issuer's public offering that closed on March 6, 2024. On August 7, 2025, Do & Rickles Investments, LLC purchased 5,000 warrants at a combined purchase price of $2.00 for each share of Class A Common Stock and accompanying warrant in connection with the Issuer's public offering that closed on August 11, 2025.
    Item 4.Purpose of Transaction
     
    The Reporting Persons acquired all their securities for investment purposes only and the securities are being held as a long-term investment. The Reporting Persons intend to continuously review their investment in the Issuer and may in the future determine to acquire additional securities of the Issuer or dispose of the securities of the Issuer owned by them or take any other available course of action, including surrendering or selling shares back to the Issuer for tax withholding obligations. Notwithstanding anything contained herein, the Reporting Persons specifically reserve the right to change their intention with respect to any or all of such matters. Mr. Do is the President and Chief Executive Officer of the Issuer and acquired his securities in that capacity. As a result, Mr. Do may have influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Other than as described above, the Reporting Persons do not have any present plans or proposals as of the date hereof that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, as part of ongoing evaluation of their investment and investment alternatives, each Reporting Person may consider such matters and, subject to applicable law, may formulate a plan or proposal with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the Board of Directors of the Issuer, other shareholders of the Issuer or other third parties regarding such matters.
    Item 5.Interest in Securities of the Issuer
    (a)
    The Reporting Persons beneficially own an aggregate of 399,018 shares of Class A Common Stock as follows: (i) 907 shares of Class A Common Stock held directly by Cuong Do, (ii) 9,992 shares of Class A Common Stock held directly by Do & Rickles Investments, LLC, (iii) warrants held directly by Do & Rickles Investments, LLC to purchase 5,050 shares of Class A Common Stock, and (iv stock options held directly by Cuong Do to purchase 383,069 shares of Class A Common Stock. Mr. Do maintains beneficial ownership, including dispositive and voting control, over Do & Rickles Investments, LLC, as its sole member. The percentage ownership is calculated based upon 7,541,539 shares of Class A Common Stock outstanding as of March 23, 2026, as provided by the Issuer, plus an additional 388,119 shares of Class A Common Stock issuable upon the exercise of warrants and stock options that are exercisable within 60 days of the date hereof.
    (b)
    Mr. Do has the sole power to vote or to direct the vote, sole power to dispose or to direct the disposition of all shares beneficially owned by him and Do & Rickles Investments, LLC, of which Mr. Do is the sole member.
    (c)
    The Reporting Persons did not engage in any transactions in shares of the Issuer's Common Stock during the past 60 days.
    (d)
    Not applicable.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    With Mr. Do serving as the President and Chief Executive Officer of the Issuer, from time to time, the Reporting Persons have received, and may in the future receive, restricted stock units, option grants or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements. Pursuant to Rule 13d-1(k) promulgated under the Exchange Act, the Reporting Persons have entered into an agreement attached hereto as Exhibit 99.2, with respect to the joint filing of this Schedule 13D and any amendment or amendments hereto.
    Item 7.Material to be Filed as Exhibits.
     
    Exh 99.1 BioVie Inc. 2019 Omnibus Equity Incentive Plan (Amended and Restated through November 10, 2025) Exh 99.2 Joint Filing Agreement

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    DO CUONG V
     
    Signature:/s/ Cuong Do
    Name/Title:Cuong Do, Individually
    Date:03/25/2026
     
    Do & Rickles Investments, LLC
     
    Signature:/s/ Cuong
    Name/Title:Cuong Do, Member
    Date:03/25/2026
    Get the next $BIVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIVI

    DatePrice TargetRatingAnalyst
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    SEC Filings

    View All

    SEC Form 10-Q filed by BioVie Inc.

    10-Q - BIOVIE INC. (0001580149) (Filer)

    5/11/26 4:56:35 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by BioVie Inc.

    SCHEDULE 13D - BIOVIE INC. (0001580149) (Subject)

    3/25/26 5:00:26 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by BioVie Inc.

    10-Q - BIOVIE INC. (0001580149) (Filer)

    2/6/26 5:01:18 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Palumbo Joseph M

    4 - BIOVIE INC. (0001580149) (Issuer)

    1/9/26 5:03:29 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Kim Joanne Wendy

    4 - BIOVIE INC. (0001580149) (Issuer)

    1/9/26 5:03:04 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rogich Sigmund

    4 - BIOVIE INC. (0001580149) (Issuer)

    1/9/26 5:02:46 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2

    CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), the Company's investigational oral drug candidate that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathwa

    5/27/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

    -Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense). An estimated 15 million U.S. adults reported having long COVID between 2022 and 2023, with 3.8 million experiencing significant lim

    5/26/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

    CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last patient evaluation visit has been completed for the Company's SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson's disease. "With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was designed to assess bezisterim's magnitude of therapeutic impact on a s

    5/18/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Do Cuong V bought 10,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    3/6/24 5:12:41 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    12/1/23 6:26:32 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

    Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

    7/22/22 7:51:28 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities reiterated coverage on BioVie with a new price target

    B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

    11/30/21 8:23:48 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Financials

    Live finance-specific insights

    View All

    BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

    -Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense). An estimated 15 million U.S. adults reported having long COVID between 2022 and 2023, with 3.8 million experiencing significant lim

    5/26/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

    CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last patient evaluation visit has been completed for the Company's SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson's disease. "With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was designed to assess bezisterim's magnitude of therapeutic impact on a s

    5/18/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

    CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim's mechanism of action could potentially address the pathology and progression of neurodegenerative diseases, including Parkinson's disease. To register, click here. The event will provid

    4/27/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Leadership Updates

    Live Leadership Updates

    View All

    BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

    The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

    5/5/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

    CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or

    6/4/24 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces the Appointment of a New Chief Medical Officer

    RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (

    11/1/21 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioVie Inc.

    SC 13G - BIOVIE INC. (0001580149) (Subject)

    10/25/24 4:01:25 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioVie Inc.

    SC 13D/A - BIOVIE INC. (0001580149) (Subject)

    6/25/24 7:47:33 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

    SC 13D/A - BIOVIE INC. (0001580149) (Subject)

    3/10/23 5:15:43 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care